Translation (biology)

• 1. Introduction

  ›

  Translation is the cellular process by which proteins are built from RNA templates, and without it, no living thing could function for even a moment. Every time a cell needs a new protein, it turns to this molecular assembly line. The instructions arrive as messenger RNA. The machinery that reads those instructions is called a ribosome. And the product is a chain of amino acids that will fold into something capable of doing real work inside the body.

  Three nucleotides at a time, the ribosome reads the mRNA sequence. Each trio, called a codon, specifies exactly one amino acid. The rules matching codons to amino acids are what biologists call the genetic code. That code is nearly universal across all life on Earth.

  What makes this process remarkable is not just its precision, but its sheer scale. Every cell runs this machinery continuously, producing thousands of different proteins. And yet the system is also regulated, error-prone in controlled ways, and deeply entwined with cancer, immunity, and antibiotic resistance. The questions worth asking are: how does a ribosome actually read RNA, what happens when the process goes wrong, and why does this one cellular event sit at the center of so much medicine?

• 2. The Ribosome Factory

  ›

  A ribosome is not a single molecule but a complex assembly of proteins and ribosomal RNA, described in the source as the factory where amino acids are assembled into proteins. In eukaryotic cells, it consists of two subunits: a small 40S subunit and a large 60S subunit. These come together specifically to perform translation, and they separate again when the job is done.

  The ribosome has two key binding sites for the small RNA molecules that carry amino acids. The aminoacyl site, known as the A site, receives the incoming charged transfer RNA. The peptidyl and exit site, called P/E, holds the growing chain. Ribosomes move in one direction along messenger RNA, from the 5' end toward the 3' end, reading codons in sequence.

  Transfer RNAs, or tRNAs, are the adaptor molecules that bridge the RNA code and the amino acid world. Each tRNA is a short noncoding RNA chain of 74 to 93 nucleotides. It carries an amino acid at one end and an anticodon at the other. The anticodon is a triplet complementary to the mRNA codon for that amino acid. Enzymes called aminoacyl tRNA synthetases catalyze the attachment of the correct amino acid to its matching tRNA. A tRNA carrying its amino acid cargo is described as charged.

  When a charged tRNA arrives at the A site and pairs correctly with the codon on the mRNA, a peptide bond forms between the new amino acid and the growing chain held at the P/E site. The chain transfers to the A-site tRNA. The ribosome then shifts one codon down the mRNA, a step powered by hydrolysis of GTP bound to the translocase EEF2, and the cycle repeats.

• 3. Starting the Process

  ›

  Initiation is the step that commits a ribosome to a particular mRNA, and in eukaryotes it is tightly controlled. The small 40S ribosomal subunit binds near the 5' cap of the mRNA with the help of a set of proteins called initiation factors. Among these, eIF4E is specifically the cap-binding protein. Binding of the 5' cap by eIF4E is considered the rate-limiting step of this mode of initiation.

  The initiation factor eIF3 associates with the 40S subunit and prevents premature joining by the large 60S subunit. It also interacts with the eIF4F complex, which includes eIF4A, eIF4E, and eIF4G. The protein eIF4G acts as a scaffold, linking eIF3 to eIF4E and eIF4A directly. eIF4A is an ATP-dependent RNA helicase that unwinds secondary structures in the mRNA to clear the path for scanning. A poly(A)-binding protein also joins this complex and has been implicated in circularizing the mRNA during translation.

  The assembled 43S preinitiation complex scans along the mRNA in the 3' direction until it reaches the start codon, which is typically AUG. In eukaryotes and archaea, the amino acid encoded by AUG at the start position is methionine. Once the start codon is found, the large 60S subunit joins, forming the complete 80S ribosome, and elongation begins.

  Not all translation begins at the 5' cap. A separate pathway called cap-independent initiation uses an internal ribosome entry site, or IRES, which allows the ribosome to bind directly near the start codon. This route is especially important during cellular stress, when overall translation is suppressed but specific mRNAs encoding survival factors still need to be read. Apoptosis responses and stress-induced programs depend on this bypass.

• 4. Elongation and Errors

  ›

  Once the 80S ribosome is assembled, elongation proceeds through a repeating three-step cycle: positioning the correct aminoacyl-tRNA at the A site with the help of the elongation factor eEF1, forming the peptide bond, and shifting the mRNA by one codon using eEF2. Amino acids are added one at a time at the C-terminus of the growing chain, so translation runs amine-to-carboxyl.

  The rate at which this happens differs significantly between cell types. Prokaryotic ribosomes can incorporate up to 17 to 21 amino acid residues per second, while eukaryotic ribosomes move at up to 6 to 9 residues per second. For a protein containing n amino acids, the process consumes 4n-1 high-energy phosphate bonds. Translation is, by that measure, one of the most energy-demanding activities in a cell.

  Ribosomes are generally accurate, but not perfect. The estimated rate of misincorporated amino acids falls between 1 in 10 to the 5th power and 1 in 10 to the 3rd power, depending on experimental conditions. Premature abandonment of translation occurs at roughly 10 to the negative 4th events per translated codon. When a ribosome stalls, a process called mRNA no-go decay can result in endonucleolytic cleavage of the stuck tRNA. Stalling also influences how newly made proteins fold, since pausing gives the emerging chain time to adopt a structure before leaving the ribosome.

  Aminoacyl tRNA synthetases that incorrectly pair a tRNA with the wrong amino acid create mischarged aminoacyl-tRNAs. These lead to mistranslation: the wrong amino acid ends up at a position in the final protein. This mistranslation happens naturally at low levels in most organisms. In certain cellular environments, however, the rate increases, and sometimes that increase actually benefits the cell.

• 5. Termination and Readthrough

  ›

  Three codons on the mRNA serve as stop signals: UAA, UAG, and UGA. When the ribosome's A site reaches one of these, no tRNA can pair with it. Instead, a release factor protein called eRF1 recognizes all three stop codons and triggers disassembly. A second factor, eRF3, is a ribosome-dependent GTPase that assists eRF1 in releasing the completed polypeptide. Once the chain is released, the ribosome breaks apart into its subunits, which are then available for recycling.

  Some human genes have stop codons that are surprisingly leaky. The source identifies a small number of genes in the human genome where the nearby RNA sequence makes termination inefficient, allowing readthrough of up to 10% of stop codons. In certain of those genes, the extra sequence beyond the stop codon encodes a functional protein domain, producing a distinct protein isoform. This process has been named functional translational readthrough.

  Drugs or specific sequence motifs in the mRNA can also alter the ribosomal structure so that near-cognate tRNAs bind to a stop codon instead of the release factors. When that happens, translation simply continues until the ribosome hits the next stop codon. Understanding these leaky stop codons has implications for genetic diseases caused by premature stop mutations, where restoring some degree of readthrough could partially rescue protein function.

• 6. Regulation and Cancer

  ›

  Translation is one of the largest energy expenditures in any cell, and the cell governs it through a layered set of controls. One key regulator is eIF2, whose phosphorylation at the alpha subunit stalls protein synthesis globally. This shutdown occurs under amino acid starvation and after viral infection. A second regulator, called 4EBP, binds directly to eIF4E and blocks its interaction with eIF4G, halting cap-dependent initiation. Growth factors counter this by phosphorylating 4EBP, which reduces its grip on eIF4E and permits protein production to resume.

  Cancer has an unusually close relationship with translation. Several major oncogenic signaling pathways, including RAS-MAPK, PI3K/AKT/mTOR, MYC, and WNT-beta-catenin, ultimately reprogram the cell through changes in translation rather than transcription alone. Cancer cells more commonly adjust the levels of existing translation factors than genetically alter the factors themselves. During metabolic stress, cancer cells translate mRNAs that help them survive. One documented example is the expression of AMPK in various cancers, whose activation can allow the cancer to escape apoptosis triggered by nutrition deprivation.

  Certain viruses exploit the translation machinery in a different way: they cleave the portion of eIF4G that binds eIF4E, disabling cap-dependent translation in the host cell while their own cap-independent mRNAs continue to be translated. The asymmetry gives the virus a decisive advantage.

  Several antibiotics act by targeting ribosomes. Among them are anisomycin, cycloheximide, chloramphenicol, tetracycline, streptomycin, erythromycin, and puromycin. Because prokaryotic ribosomes are structurally different from eukaryotic ones, many of these drugs can selectively disable bacterial translation without harming the host. That structural difference is the basis for one of the most important classes of drugs in medicine, and future cancer therapies may extend the same logic to disrupt the translation machinery of tumor cells.

• 7. Amino Acid Substitution

  ›

  Activated T cells secrete interferon-gamma, which triggers a shortage of the amino acid tryptophan inside the cell by upregulating the enzyme indoleamine 2,3-dioxygenase 1, abbreviated IDO1. Rather than halting protein synthesis at tryptophan codons, the cell continues translation by inserting phenylalanine in tryptophan's place. The resulting proteins are called W to F substitutants, using the single-letter amino acid codes.

  These substitutants are abundant in certain cancer types and have been linked to increased IDO1 expression. Functionally, W to F substitutants can impair the activity of the proteins they appear in. This phenomenon illustrates how translation can be biochemically flexible in ways that matter clinically. The link between IDO1 upregulation, tryptophan depletion, and cancer-associated mistranslation opens a path toward therapies that target this substitution mechanism directly.